Stockreport

Asahi Kasei Pharma Strengthens Global Reach with Exclusive License Agreement for anti-CX3CR1 Antibody

ASAHI KAISEI CRP UNSP/ADR  (AHKSY) 
NASDAQ:AMEX Investor Relations: asahi-kasei.co.jp/asahi/en/ir
PDF TOKYO & NOVI, Mich. & DÜSSELDORF, Germany--(BUSINESS WIRE)--Asahi Kasei Pharma has taken another step in its transformation into a global specialty pharmaceuticals c [Read more]